The UK’s National Institute for Health and Care Excellence (NICE) has recommended originator pertuzumab with intravenous biosimilar trastuzumab and chemotherapy for the treatment of breast cancer.
Original Article: UK’s NICE recommends pertuzumab with biosimilar trastuzumab